At an interview about the importance of the EFIC-GRÜNENTHAL Grant and special needs in pain research, with focus on major advances in the treatment of patients suffering from chronic pain. Dott. Alberto Grua, Member of the Corporate Executive Board, CCO EU, Australia and North-America, Grünenthal Group Dr. Matthias Müller, MD, MSc, SVP, Head of Medical Affairs, Grünenthal Europe & Australia and North America
The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 26 percent of revenues in 2012.
Encouraging innovative pain research projects
Since 2004 Grünenthal GmbH in cooperation with the European Pain Federation EFIC® supports young scientists at an early stage of their experimental projects on clinical or human volunteer-based pain research. The EFIC-GRÜNENTHAL Grant is totaling 200,000 EUR, research grants are valued at up to EUR 40,000 per project.The application deadline for this year’s EFIC-GRÜNENTHAL Grant is set on 31 December 2014.